112 related articles for article (PubMed ID: 25575863)
21. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
22. Novel chitosan-functionalized spherical nanosilica matrix as an oral sustained drug delivery system for poorly water-soluble drug carvedilol.
Sun L; Wang Y; Jiang T; Zheng X; Zhang J; Sun J; Sun C; Wang S
ACS Appl Mater Interfaces; 2013 Jan; 5(1):103-13. PubMed ID: 23237208
[TBL] [Abstract][Full Text] [Related]
23. Strategies and advances in nanomedicine for targeted siRNA delivery.
Nimesh S; Gupta N; Chandra R
Nanomedicine (Lond); 2011 Jun; 6(4):729-46. PubMed ID: 21718181
[TBL] [Abstract][Full Text] [Related]
24. Self-assembled nanoparticles based on galactosylated O-carboxymethyl chitosan-graft-stearic acid conjugates for delivery of doxorubicin.
Guo H; Zhang D; Li C; Jia L; Liu G; Hao L; Zheng D; Shen J; Li T; Guo Y; Zhang Q
Int J Pharm; 2013 Dec; 458(1):31-8. PubMed ID: 24140544
[TBL] [Abstract][Full Text] [Related]
25. Puerarin attenuates pressure overload-induced cardiac hypertrophy.
Yuan Y; Zong J; Zhou H; Bian ZY; Deng W; Dai J; Gan HW; Yang Z; Li H; Tang QZ
J Cardiol; 2014 Jan; 63(1):73-81. PubMed ID: 23906530
[TBL] [Abstract][Full Text] [Related]
26. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery.
Park S; Jeong EJ; Lee J; Rhim T; Lee SK; Lee KY
Carbohydr Polym; 2013 Jan; 92(1):57-62. PubMed ID: 23218265
[TBL] [Abstract][Full Text] [Related]
27. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
Bao X; Wang W; Wang C; Wang Y; Zhou J; Ding Y; Wang X; Jin Y
Biomaterials; 2014 Sep; 35(29):8450-66. PubMed ID: 24997481
[TBL] [Abstract][Full Text] [Related]
28. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
29. A novel peptide for efficient siRNA delivery in vitro and therapeutics in vivo.
Pan R; Xu W; Yuan F; Chu D; Ding Y; Chen B; Jafari M; Yuan Y; Chen P
Acta Biomater; 2015 Jul; 21():74-84. PubMed ID: 25861950
[TBL] [Abstract][Full Text] [Related]
30. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
Lister K; Autelitano DJ; Jenkins A; Hannan RD; Sheppard KE
Cardiovasc Res; 2006 Jun; 70(3):555-65. PubMed ID: 16533503
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
[TBL] [Abstract][Full Text] [Related]
32. Hydrophobically modified carboxymethyl chitosan nanoparticles targeted delivery of paclitaxel.
Sahu SK; Maiti S; Maiti TK; Ghosh SK; Pramanik P
J Drug Target; 2011 Feb; 19(2):104-13. PubMed ID: 20367067
[TBL] [Abstract][Full Text] [Related]
33. Chitosan-based formulations for delivery of DNA and siRNA.
Mao S; Sun W; Kissel T
Adv Drug Deliv Rev; 2010 Jan; 62(1):12-27. PubMed ID: 19796660
[TBL] [Abstract][Full Text] [Related]
34. Development and evaluation of carvedilol-loaded transdermal drug delivery system: In-vitro and in-vivo characterization study.
Kshirsagar SJ; Bhalekar MR; Mohapatra SK
Drug Dev Ind Pharm; 2012 Dec; 38(12):1530-7. PubMed ID: 22356303
[TBL] [Abstract][Full Text] [Related]
35. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
[TBL] [Abstract][Full Text] [Related]
36. Analysis of p53 and NF-κB signaling in modulating the cardiomyocyte fate during hypertrophy.
Chatterjee A; Mir SA; Dutta D; Mitra A; Pathak K; Sarkar S
J Cell Physiol; 2011 Oct; 226(10):2543-54. PubMed ID: 21792911
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells.
Maya S; Kumar LG; Sarmento B; Sanoj Rejinold N; Menon D; Nair SV; Jayakumar R
Carbohydr Polym; 2013 Apr; 93(2):661-9. PubMed ID: 23499109
[TBL] [Abstract][Full Text] [Related]
38. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
39. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
40. Nanotechnology for in vivo targeted siRNA delivery.
Dahlman JE; Kauffman KJ; Langer R; Anderson DG
Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
